The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Estrogen Receptor-Positive,Human Epidermal Growth Factor Receptor 2 (HER2)—Negative Metastatic Breast Cancer Breast Cancer Treated with CDK4/6 inhibitors
Pan-Immune-Inflammation-Value in Metastatic Breast Cancer Breast Cancer Treated with CDK4/6 inhibitors
Keywords:pan immune-inflammation value, breast cancer, ribociclib, palbociclib
Background: To define the prognostic value of pan immune-inflammation value (PIV) in patients with Estrogen receptor (ER)-positive, Human epidermal growth factor receptor 2(HER2)- negative metastatic breast cancer.
Methods: We retrospectively evaluated the prognostic impact of PIV on the survival of patients with ER+, HER2- metastatic breast cancer receiving CDK4/6 inhibitors. The cut-off value of CRP/alb, N/L, L/M, PLT/L, SII, and PIV is determined by using the receiver operating characteristic(ROC) analysis. Progression-free survival (PFS) comparisons of palbociclib and ribociclib treatments, and CRP/albumin, neutrophil/lymphocyte ratio, systemic immune inflammation index, and PIV were performed using Kaplan-Meier curves and median survival times. PIV was calculated as neutrophil x platelet x monocyte /lymphocyte count (109/L).
Results: Ninety-one patients were included in this study. The patients' mean age was 58.4±11.7 years. At a median follow-up of 48 months, 11%(10) of patients died. 53.8%(49) of patients had the metastatic disease when they were diagnosed. 87.9%(80) were menopausal, and 39.6%(36) received ribociclib, 60.4%(55) palbociclib. The cutoff value of PIV 476.5 is calculated using the receiver operating characteristic(ROC) analysis. The Cox regression analysis for PFS showed that PIV (HR:4.68;p=0.022) and drugs combined with CDK4/6 (HR:4.68;p=0.022) were the only independent prognostic markers for PFS. Median progression-free difference was not significantly significant between ribociclib and palbociclib groups (27.9 vs 25.5 months respectively;%95 CI,25.9-29;p=0.654).
Conclusions: PIV is a simple and inexpensive, easily calculated marker to predict the survival of patients with ER-positive, HER2-negative metastatic breast cancer. This technique can assist physicians in putting tailored and focused treatment plans in place. Between ribociclib and palbociclib, there is no statistically significant difference in PFS.
How to Cite
Copyright (c) 2022 Chronicles of Precision Medical Researchers
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.